The Intersection of Life Sciences and Business

Back Bay teams begin with a nuanced understanding of the clinical and scientific underpinnings of new therapeutics and medical technologies. To this, we add our expertise in business and financial markets, as well as our knowledge of what drives R&D, commercial and transactional success.

We partner with clients to create actionable strategies for product development, commercial success and transactional execution that drive growth and create value across the product and corporate continuum. Our recommendations balance the needs of the patient, the vision of the company and returns for the investor, to provide workable solutions to the complex decision-making demanded by scientific and clinical innovation.

We have successfully completed more than 1,000 engagements spanning every phase of the product life cycle — from gleam-in-the-eye technologies to billion-dollar brands. We take pride in the number of clients who refer and re-engage us as new challenges emerge in the dynamic fields of life science and medical technology.

For every strategy engagement, Back Bay dedicates senior leadership and highly-experienced teams who have broad, diverse life science experience. Our teams communicate consistently and efficiently to provide insightful strategies to companies of all sizes, tackling challenges that range from early-stage candidates to leading brands across the biopharmaceutical and medical technology sectors.

From Johnson & Johnson to Centrexion, from Novo Nordisk to Albireo, across every sector, stage and geography, Back Bay Life Science Advisors partners with the organizations that sustain and grow the life science industry.  

Growth Strategies Built on Superior Data Analytics

Data analytics is a cornerstone of all Back Bay assignments. Using a comprehensive range of data sources and the highly skilled analytic capabilities of the Back Bay team, we ensure our recommendations are always well supported and defensible.

Back Bay is an expert in the development of bespoke forecasting models and databases that are designed for the needs of the client, the nature of the project and the eventual audiences for the output. In addition, we build robust and client-ready deliverables that ensure models continue to evolve as new data becomes available, and that can be used long after the engagement ends. 

This robust technical, clinical, commercial and transactional analysis enables us to create clarity out of ambiguity and serves as the foundation for well-informed growth strategies for our clients.

Strategic M&A, Partnerships and Licensing for Global Life Sciences

Back Bay is among the very few advisors that offer both integrated strategy and investment banking solutions. Every financial advisory engagement taps into the firm’s deep experience with deal execution and ability to provide data-driven, customized insights.

We negotiate on our clients’ behalf from the strength of our analytics, insights, research-intensive knowledge and deal experience.

Our investment banking team has more than $23 billion in transactional experience, has forged strong relationships with major stakeholders and offers a global reach. This ensures that Back Bay’s clients are presented with the thoughtful and strategic options that result in successful transactions.

Back Bay’s investment banking clients benefit from:

• Senior banking presence with extensive life science relationships and experience 
• Adept financial approach that combines scientific, clinical and commercial insights 
• Ability to convert research-based insight into credible positioning and valuation considerations 
• Expertise in negotiating complex deals and creative structures

Negotiating complex M&A, partnership or licensing deals for: 

• Biotech, pharma and medical technology companies seeking to merge, acquire or sell 
• Companies looking to engage in strategic asset transactions (licensing and partnering) on a regional or global basis 
• Small and mid-size companies looking to extend and leverage their corporate/business development capabilities 
• Venture-backed companies requiring an assessment of strategic alternatives — our analysis and advice becomes the basis for our execution of strategic M&A, partnerships or licensing deals 
• PE and VC investors seeking guidance on portfolio strategy, investments, new financing rounds and transactions 
• Academic institutions seeking options for their early-stage programs, including out-licensing, partnerships and company formation

Experienced, Insightful Life Science Fairness Opinion and Valuation

Back Bay Life Science Advisors provides experienced best-in-class M&A advisory and investment banking services, including sophisticated pipeline and platform valuations, as well as specialized services such as Fairness Opinions and Valuations. For our clients involved in global biopharma and medtech mergers, acquisitions, divestitures and other sophisticated corporate transactions, we help our client boards, management teams and investors confidently make informed decisions throughout the complexities of life sciences business and corporate development.

Our senior bankers have provided fairness opinions and valuation since inception of the process in the Delaware courts more than three decades ago. We understand the intricacies of scientific development and life science complexities and integrate this within the real-life deal and legal frameworks and timing, for an unparalleled, nuanced understanding of life science transactions.

Back Bay’s fairness opinion offering is a fully integrated part of our life sciences investment banking practice and execution capabilities. We bring together life sciences strategy consulting and investment banking to meet the global need for exacting, independent insight, strategy and deal execution for life sciences companies.